Implantable pelvic neurostimulators to restore erectile function: from concept to practice

Three of seven authors on this penile nerve-implant review work for the company selling the device

Journal: Nature Reviews Urology | Published: 2026-01-06 | Type: Review | PMID: 41491267 Authors: Burnett AL (Johns Hopkins Brady Urological Institute); Sturny MN, Stergiopoulos N, Fraga-Silva RA (Swiss Federal Institute of Technology, Lausanne — also employees of Comphya SA); Costello AJ (Australian Prostate Centre); Dundee P (St. Vincent's Private Hospital, Melbourne); Glina S (Faculdade Medicina ABC, São Paulo) Funding/COI: Funding not listed. Three of the seven authors are employees of Comphya SA, the company developing the CaverSTIM device discussed in the review.

Summary

This is a narrative review, not a clinical trial: it argues that electrically stimulating pelvic nerves could restore erections in men with nerve damage from spinal cord injury, radical prostatectomy, or aging, tracing the concept back through 150 years of animal and human stimulation experiments. It reports no new patient data of its own.

Claims

• Electrical stimulation of pelvic nerves has produced erection responses in experimental work dating back roughly 150 years
• Cited clinical investigations report "recovery of erection" after implantation of pelvic neurostimulators in men with spinal cord injury or after radical prostatectomy — no pooled sample size or effect size is given in the abstract
• Authors frame penile neurostimulation as an emerging subspecialty of sexual medicine

Study Quality

The abstract describes no systematic search strategy, inclusion criteria, or quality appraisal of the underlying studies — this is a narrative account making a case for a technology, not a synthesis weighing evidence quality. None of the "recovery of erection" claims come with sample sizes, effect sizes, or trial design details in the material provided.

Note: the methods/results/conclusions text supplied alongside this abstract describes a literature review of stem cell therapy, platelet-rich plasma, and shockwave therapy — a different topic entirely, citing a 2021 SMSNA position statement unrelated to neurostimulation. That content does not correspond to this paper's title or abstract and was excluded from this write-up as a data-source mismatch.

Red Flags

• Three of seven authors are employees of Comphya SA, the company developing CaverSTIM, the device central to the review's thesis
• No funding source disclosed at all, despite the direct commercial stake of several authors
• Abstract language runs promotional ("revolutionary new therapeutic approach," "authentic restorative therapy") rather than descriptive
• No systematic methodology, so selective citation of favorable studies can't be ruled out
• No sample sizes or statistics accompany the central "recovery of erection" claims

Strengths

• Senior author Burnett is an established academic urologist at Johns Hopkins with no reported industry ties
• Published in a high-impact, editorially reviewed journal (Nature Reviews Urology)
• Supplies genuinely useful historical context on 150 years of pelvic nerve stimulation research

Verdict

Read this as a positioning paper for penile neurostimulation, not a neutral referee of it — nearly half the author list draws a paycheck from the company selling the leading device in this space, funding is undisclosed, and the review is narrative rather than systematic, meaning there's no way to check what got left out. Worth it for the history lesson, not for the pitch.